For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating-and possibly even ...

Gilead has agreed to provide the drug at cost and to share its intellectual property with generic manufacturers who can ...

For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even ...

Uganda is set to introduce a new long-acting HIV prevention drug, Lenacapavir, in 2026 under a United States-funded ...

What if the presence of a well-known but misunderstood viral protein explains why some people living with HIV (PLWH) never ...

Researchers at Case Western Reserve University identified for the first time how HIV enters a dormant state in infected cells that allows the virus to “hide” from the immune system and current ...

Lenacapavir is a long-acting injectable antiretroviral drug developed by Gilead Sciences. It is administered just twice a year and has demonstrated over 99.9% effectiveness in preventing HIV ...

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of ...

A federal grant for HIV research is part of $15.7 million the National Institutes for Health awarded to the Wertheim UF ...

New partnership will join others to expand access to generic lenacapavir for millions more people at risk of HIV in high-burden countries—bringing the world closer to ending the epidemic - Kenya ...

The National Institutes of Health (NIH) has awarded CUNY SPH Assistant Professor Philip Kreniske $5,115,391 for a ...